Controversy surrounds the efficacy and safety of 17b-estradiol (E 2 )-mimetic therapies to women for treatment of menopausal symptoms. An important question is the nature of the trophic actions of E 2 -mimetics in the brain for behavioral processes versus in the periphery for beneficial effects related to osteoporosis, or unwanted proliferative effects in the reproductive tissues, such as mammary glands and uterus. Of recent interest are the effects of selective estrogen receptor modulators, which can have tissue specific actions, for these processes. In the present study, the effects were determined of E 2 alone, or co-administered with a selective estrogen receptor modulator, raloxifene, for anxiety-like, depression-like, and trophic peripheral effects in ovariectomized rats that were exposed to a chemical carcinogen (7,12-dimethylbenz(a)anthracene), or not. Once per week, rats were administered vehicle, E 2 (0.09 mg/kg) and/or raloxifene (1 mg/kg) subcutaneously 44-48 h before testing in a positive control, E 2 -dependent behavior (lordosis), depression (forced swim test), and anxiety (elevated plus maze) behavioral assays. In addition to behavioral endpoints, incidence and number of tumors, and tumor, pituitary gland, and uterine weight 14 weeks after carcinogen-exposure, and weekly hormone treatments, were analyzed. Rats administered 7,12-dimethylbenz(a)anthracene had an increased number and size of tumors, compared with vehicle treatment. E 2 + raloxifene increased the number of tumors.
Introduction
Menopause is characterized by ovarian cessation in the secretion of steroids, such as 17b-estradiol (E 2 ) (Lund, 2008) . Given the important role of E 2 throughout adult life, this abrupt reduction in ovarian E 2 can produce such severe physical and psychological symptoms in an estimated one-quarter of menopausal women that pharmacological interventions will be sought (Dickson and Henriques, 1992; Lund, 2008) . Effects on bone health, and mood/quality of life, are some of the major reasons for women to seek menopausal hormone treatments, which include E 2 -mimetics (Bhavnani and Strickler, 2005; Stovall and Pinkerton, 2008) . However, these types of E 2 -mimetic treatments can increase the risks of some women for cardiovascular complications and reproductive cancers (breast, uterine; Colditz et al., 1995; Collaborative Group on Hormonal Factors in Breast Cancer, 1997; Magnusson et al., 1999) . A similar pattern is observed in preclinical rodent models. For example, we have demonstrated that the administration of E 2 to female rats can have positive effects to reduce anxiety behaviors, but that it can also increase carcinogen-induced tumor incidence and uterine proliferation (Walf and Frye, 2009a, 2009b) . The source of positive and negative effects of estrogens in the central nervous system and peripheral tissues may be related to divergent mechanisms of action.
The greater understanding of the cellular mechanisms of estrogens in specific tissues in recent years has led to the formulation of E 2 -mimetics, called selective estrogen receptor modulators (SERMs). SERMs, like estrogen receptor (ER) agonists or antagonists, bind ERs, and can function as either estrogen agonists or antagonists in different types of tissue (Katzenellenbogen and Katzenellenbogen, 2002) . The three characteristics that interact and define SERMs are that: (i) ER expression differs across tissues, (ii) ER conformation differs for ligand binding, and (iii) there is different co-regulator protein expression and binding to the ER (Riggs and Hartmann, 2003) . The prototypical SERM is tamoxifen, which has been used clinically to treat ER-positive breast cancer for over 50 years because of its actions as an ER antagonist in the breast (MacGregor and Jordan, 1998; Wang et al., 2009 ). However, tamoxifen has unwanted side effects, including increasing the risk of thromboembolisms, stroke, and endometrial cancer (Jordan and Morrow, 1999) . Raloxifene is a more recently characterized SERM that was approved for use in 1997 by the US Food and Drug Administration for osteoporosis prevention (MacGregor and Jordan, 1998) . Raloxifene is an agonist on bone (Delmas et al., 1997; Ettinger et al., 1999) and lipid metabolism (Delmas et al., 1997) , but an antagonist in the breast (Cummings et al., 1999) and uterus (Delmas et al., 1997; Mitlak and Cohen, 1999) . There is some indication in clinical studies that raloxifene can be an agonist in the central nervous system. In a clinical trial of postmenopausal women with osteoporosis, raloxifene was not associated with negative changes on affect or cognition (Nickelsen et al., 1999) . Among healthy, postmenopausal women, raloxifene decreased anxiety/ fear self-rated scores (Strickler et al., 2000) and quality of life measures (Utian et al., 2004) at a 12-month follow-up. Similarly, depression and anxiety scores were reduced in non-depressed postmenopausal women in a randomized, double-blind study on prevention of osteoporosis by raloxifene (Jarkova et al., 2002) . A question of continued interest is the role of raloxifene for central nervous system function that may be complementary to its positive effects in the bone and other ER-rich tissues.
To date, there are a handful of published studies on rodents that have shown the beneficial effects of raloxifene for central nervous system function. In rats, raloxifene increases potassium-stimulated acetylcholine release (Gibbs et al., 2004) , choline acetyltransferase activity (Wu et al., 1999) , and glutamate ± amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor and N-methyl-D-aspartic acid receptor binding (Cyr et al., 2001a (Cyr et al., , 2001b , in the hippocampus. Functionally, raloxifene produces similar taste aversion in young, ovariectomized rats as does tamoxifen (Fudge et al., 2009) , and can reduce the immobility of rats in a 2-day forced swim test (Karahancer et al., 2008) . Raloxifene may have neuroprotective effects. In support, following experimentally-induced traumatic brain injury, male rats have fewer sensorimotor and working memory deficits, despite little evidence of reduced lesion size, following post-injury administration of raloxifene (3 mg/kg at 15 min, and hours 24, 48, 72, and 96; Kokiko et al., 2006) . Neuroprotective effects in in-vitro neurotoxicity models (e.g. toxicity because of glutamate, hydrogen peroxide, b-amyloid) have been shown with the application of raloxifene (O'Neill et al., 2004) . Although these studies suggest the beneficial effects of raloxifene in the central nervous system, the effects of raloxifene for these central nervous system processes in relation to the trophic effects in the body are not known. Moreover, raloxifene acts as an agonist in some tissues when no E 2 is present, but can have antagonistic effects (O'Neill et al., 2004) or agonistic effects (Walf and Frye, 2006) in the presence of E 2 . As such, this study tested the hypothesis that E 2 and raloxifene, alone or in combination, would have different behavioral (anxiety, depression, sexual responding) and peripheral trophic effects (tumor, uterus, pituitary growth). It was predicted that E 2 would have clear behavioral effects and trophic actions in peripheral tissues; whereas, raloxifene would have a greater effect on behavior than on growth in the periphery at this dosing. Furthermore, it was predicted that raloxifene in conjunction with E 2 may reverse the effects of E 2 alone.
Methods
The methods utilized in this study conform to the accepted standards of humane animal use and were approved by the Institutional Animal Care and Use Committee at The University at Albany-SUNY.
Subjects and housing
Subjects (N = 65) were adult (B8 weeks old) female, Long-Evans rats from our colony, with original breeders obtained from Taconic Farms (Germantown, New York, USA). Rats were group-housed, with three to five rats per cage. Cages were polycarbonate (45 Â 24 Â 21 cm) and contained woodchips for bedding. Rats were housed in these cages in a temperature-controlled room (21 ± 11C), on a reversed-lighting schedule (lights off at 8:00 am), in the core Laboratory Animal Care Facility of The Life Sciences Research Building at The University at Albany-SUNY. Rats had free access to commercial rodent chow and tap water in their home cages.
Ovariectomy
All rats were ovariectomized, using typical methods, under anesthesia (xylazine 12 mg/kg; Bayer Corp., Shawnee Mission, Kansas, USA and ketamine 60 mg/kg; Fort Dodge Animal Health, Fort Dodge, Iowa, USA). Surgery occurred 1 week before initiation of experimental protocol (described in Procedure section, below).
Hormone administration
Each week, rats were administered vegetable oil vehicle or E 2 (0.09 mg/kg in vegetable oil vehicle; Steraloids, Newport, Rhode Island, USA), and/or raloxifene (1 mg/kg in propylene glycol vehicle; generously supplied by Eli Lilly & Company; Indianapolis, Indiana, USA). These treatments were administered 44-48 h before behavioral testing. E 2 dosing was based upon previous studies in our lab that have shown that this regimen produces physiological E 2 levels in plasma and brain at time of testing, decreases anxiety behavior, and increases lordosis of rats when they are tested 44-48 h after injection (Frye et al., 1998; Walf and Frye, 2005a , 2005b , 2009a , 2009b . Raloxifene dosing was based upon pilot studies done in the lab in rats and mice, and the literature (Walf and Frye, 2006; Takahata et al., 2008) . Because higher dosages of raloxifene (over 1 mg/kg) disrupt estrous cyclicity, and can reduce fertility, of young rats (Hoyt et al., 1998) , a lower dosage of raloxifene was intentionally utilized so that its physiologically-relevant effects and/or interactions with E 2 could be observed and parsed out. Rats were administered these compounds once a week to allow for sufficient washout before readministration and behavioral testing the following week.
DMBA-induced tumor model
Rats are most susceptible to tumor induction in mammary glands between 45 and 60 days of age because there are high rates of glandular epithelium proliferation at this time. Administration of the chemical carcinogen, 7, 12-dimethylbenz(a)anthracene (DMBA) to intact female rats between 30 and 45 days of age produces 100% tumor incidence, but the greatest tumor severity (as per the tumor-affected animal index) is reached when DMBA is administered to rats that are 46-50 days of age (Russo and Russo, 1996) . As such, adult female rats, between 50 and 60 days of age, in this study were administered a single dosing of an inert control substance (i.e. vegetable oil) or DMBA (Sigma; St Louis, Missouri, USA), as per described methods (Walf and Frye, 2009a, 2009b) . DMBA (12.5 mg) was dissolved in vegetable oil before administration through gavage, using a curved animal feeding needle that was 3 inches long, 16-gauge, with a 3 mm diameter ball on the end. This dosing of DMBA was based upon the dose-response studies of Huggins and our laboratory (Huggins, 1965; Walf and Frye, 2009a, 2009b) . With higher dosing of DMBA (20 mg/kg) all rats survive carcinogen exposure, but there are shorter latencies to tumor growth and greater incidence of tumors, at this dosing than at lower dosages. With this high dosing, there is 100% incidence of tumors between 8 and 21 weeks following administration (Russo and Russo, 1996) . We have recently shown that lower dosing can produce discernible differences in tumor incidence with E 2 -modulation of young adult, ovariectomized rats within 14 weeks (Walf and Frye, 2009a, 2009b) . Given that these past studies in our laboratory, and the present investigation, had behavioral endpoints, it was important to use sub-optimal dosing of DMBA and a shorter latency to the study endpoint. Given these parameters, tumors that were produced were small, most clearly detectable at necropsy, and did not hamper the mobility of rats in behavioral tasks, which allowed concurrent examination of behavior and peripheral trophic effects. Mean tumor wet weights are included in Table 1 .
Procedure
Rats were randomly assigned to be administered an inert vehicle or DMBA at the beginning of the study, 1 week after ovariectomy. Rats in these conditions were then assigned to their hormone condition, which they received on a weekly basis for 14 weeks (as per Walf and Frye, 2009a, 2009b) : vehicle, E 2 , raloxifene, or E 2 + raloxifene. Rats were behaviorally tested (as described below) and, at the end of the study, tumors (if present), pituitary glands, and uterine tissue were collected and weighed.
Behavioral testing
Experimental rats were tested in the following tasks in the same order. Data were collected by trained observers and the Any-maze video-tracking system (Stoelting, Inc., Wood Dale, Illinois, USA).
Sexual behavior
Rats were tested for sexual behavior, or the lordosis posture (dorsiflexion which allows males to intromit during mating), as a measure of an E 2 -dependent behavioral response. They were tested using typical methods, which involve placing the experimental female rat in a Plexiglas chamber (50 Â 25 Â 30 cm) with a sexually-experienced male rat (Frye et al., 1998) . The lordosis quotients, or frequency of lordosis postures assumed when the female was mounted by a male, were recorded for rats for 10 mounts or 10 min, whichever occurred first, as is standard protocol for this task. The majority of female rats received 10 mounts by the sexually-experienced male rat (n = 33 of 57), and in the unlikely event that rats received fewer than four mounts (n = 5 of 57), their data were excluded from analyses. Technical difficulties precluded the analyses of data from eight rats for this measure. The n's for each group for this measure are included in the Fig. 1 legend.
Forced swim test
The forced swim test is a typically-used behavioral assay for the depression-like behavior of rodents. It was done as described earlier in detail (Frye and Walf, 2002) . Briefly, rats were placed in a cylindrical chamber (45 cm high, 20 cm diameter; Stoelting), filled to 30 cm of room temperature (301C) tap water. The amount of time rats spent swimming or struggling (as measures of activity behavior) versus immobile (as a measure of depressionlike behavior) following placement in the chamber was recorded for 10 min.
Elevated plus maze
The elevated plus maze is a typically-used behavioral assay for anxiety-like behavior of rodents. In this task, experimental rats were placed in the center of the maze, between the two closed and two open arms (Walf and Frye, 2007a) . The time spent by rats on the open arms of the maze, during the 5 min test, was recorded and used as a measure on reduced anxiety-like behavior. The number of total arm entries made by the rats was used as an index of general motor behavior in this task.
Tissue collection
Rats were euthanized by rapid decapitation. They were palpated and visually inspected to determine the presence Open symbols indicate the VEH condition and closed symbols indicate the DMBA condition. Circles, squares, triangles, and diamonds indicate VEH (n = 6 DMBA, n = 6 VEH), E 2 (n = 8 DMBA, n = 6 VEH), raloxifene (n = 5 DMBA, n = 6 VEH), and E 2 + raloxifene (n = 9 DMBA, n = 6 VEH), respectively.
of tumors. If tumors were present, they were dissected out and weighed. Pituitary glands and uteri of rats were dissected out and weighed.
Statistical analyses
Two-way analyses of variance tests were utilized to determine the effects of hormone condition and DMBA condition on all endpoints. If significant main effects were found, group differences were determined by Fisher's post hoc tests. As uterine weight can be used as a proxy for estrogenic effects of compounds, simple regression analyses were also utilized to determine the extent to which uterine weights accounted for the variability in the behavioral effects assessed. A P value of r 0.05 was considered significant and a P value of r 0.10 was considered a tendency.
Results

Peripheral trophic effects
As expected, we found that exposure to the chemical carcinogen and E 2 had trophic effects in peripheral tissues. DMBA exposure increased group tumor incidence of rats administered vehicle (87.5%), raloxifene (80%), E 2 (87.5%), or both E 2 and raloxifene (100%). There was a significant main effect of DMBA condition for the number of tumors in rats [F(1,57) = 4.26, P < 0.05], and a tendency for differences in mean wet weights [F(1,40) = 2.95, P = 0.09], in that DMBA increased both number and wet weights of tumors compared with vehicle treatment (Table 1) . There was a significant main effect of hormone condition for the number of tumors [F(3,57) = 2.67, P < 0.05], but not the wet weight of tumors. Compared to vehicle or raloxifene alone, E 2 + raloxifene significantly increased the number of tumors that developed (Table 1 ). There were no significant interactions between hormone condition and DMBA condition for the number of tumors or their wet weight.
There were no significant main effects of DMBA, or interaction between variables, for pituitary or uterine weight. Hormone condition significantly altered the pituitary [F(3,54) = 2.86, P < 0.05] and uterine weights [F(3,57) = 14.73, P < 0.01]. E 2 and E 2 + raloxifene significantly increased pituitary weights compared with vehicle treatment (Table 1 ). E 2 and E 2 + raloxifene significantly increased uterine weights compared with vehicle or raloxifene treatment alone (Table 1) .
Behavioral effects
Simple regression analyses showed that there were positive relationships between uterine weight and lordosis quotients (r 2 = 0.19, P < 0.01), immobility in the forced swim test (r 2 = 0.11, P < 0.05), and duration spent on the open arms of the elevated plus maze (r 2 = 0.11, P < 0.05). Scatter plots of these data are included at the top of each figure for these measures (Figs 1-3) .
As expected, hormone condition altered behavior in the E 2 -dependent measure, lordosis quotients [F(3,44) = 15.27, P < 0.01]. E 2 and E 2 + raloxifene significantly increased lordosis quotients compared to administration of raloxifene or vehicle (Fig. 1 ). There was no significant main effect of DMBA, or interaction between hormone and DMBA condition, for lordosis quotients.
A similar pattern was observed in the forced swim test as was shown with lordosis. There was a significant main effect of hormone treatment, but not DMBA condition or an interaction between hormone and DMBA condition, for duration spent immobile in the forced swim test [F(3,57) = 2.93, P < 0.05]. Rats administered E 2 spent significantly less time immobile in the forced swim test than did rats administered vehicle or raloxifene (Fig. 2 ). There were neither significant main effects, nor interactions, of hormone and DMBA condition for the duration spent struggling or swimming in this task (Table 2 ).
There was a slightly different pattern in the elevated plus maze following treatment. There was a significant effect of hormone condition [F(3,57) = 2.94, P < 0.05], but not DMBA condition, or the interaction between these variables, for time spent on the open arms of the elevated plus maze. Rats administered E 2 or raloxifene spent more time on the open arms than did rats administered vehicle (Fig. 3 ). There were no significant differences between hormone or DMBA condition, or the interaction between these variables, for total entries made in this task (Table 2 ).
Discussion
The results of this study partially supported our hypothesis that there would be discernible effects of E 2 and raloxifene, administered alone or when co-administered, for behavior and trophic effects in peripheral, ER-rich tissues. Rats administered DMBA had increased incidence and number of tumors, compared to inert vehicle treatment. E 2 + raloxifene increased the number of tumors compared with vehicle or raloxifene treatment alone. Administration of E 2 , or E 2 + raloxifene, but not raloxifene alone, increased pituitary and uterine weight, compared with vehicle administration. In our positive control E 2 -dependent measure of lordosis, E 2 or E 2 + raloxifene, but not raloxifene alone, increased lordosis quotients compared with vehicle administration. Administration of E 2 , compared with vehicle or raloxifene administration alone, reduced depression-like behavior in the forced swim test (i.e. decreased time spent immobile). A different pattern emerged for anxiety-like behavior in the elevated plus maze. Administration of E 2 or raloxifene alone, but not co-administration of these compounds, reduced anxiety behavior in the elevated plus maze (i.e. increased time spent on the open arms of the maze), compared with vehicle administration. Notably, the behavioral effects of raloxifene and E 2 in this study occurred without clear nonspecific effects on motor measures in the affective tasks utilized (i.e. struggling and swimming in the forced swim test and total arm entries in the plus maze). These results show that E 2 and/or raloxifene can have some effects to increase sexual responding and improve affective behavior of ovariectomized rats. E 2 can also have clear trophic actions in peripheral tissues, such as carcinogen-induced tumors, uteri, and pituitary glands, which are not apparent with raloxifene administration alone or altered by raloxifene coadministration. Thus, these data of discernible trophic effects of E 2 and raloxifene suggest that there may be divergent actions of these compounds at ER-rich brain and peripheral targets.
The present data confirm previous results on the trophic effects of E 2 in the central nervous system and periphery. We and others have shown earlier that physiological levels of E 2 that are akin to those observed in behavioral estrous increase lordosis and reduce anxiety-like and depression-like behavior, similar to the effects observed in this study (Kow and Pfaff, 2004; Pfaff, 2005; Walf and Frye, 2005a , 2005b , 2009a , 2009b Mazzucco et al., 2008) . Furthermore, there is evidence for E 2 to increase spontaneous and carcinogen-induced tumors as well as uterine proliferation (Leung et al., 2003; Walf and Frye, 2009a, 2009b) , and this predicted effect was observed in this study. However, there are some inconsistencies in the reported effects of E 2 for tumor incidence and growth in rat models that need to be addressed.
Low physiological E 2 levels can stimulate DMBA-induced tumor growth (Walf and Frye, 2009a, 2009b) , but supraphysiological E 2 dosing can inhibit this growth (Ohi and Yoshida, 1992; Callejo et al., 2005) . The different regimens of E 2 in these studies may account for these differences. In the present study, and in other recent studies in our laboratory, E 2 (0.09 mg/kg) was administered once weekly, 44-48 h before behavioral Open symbols indicate the VEH condition and closed symbols indicate the DMBA condition. Circles, squares, triangles, and diamonds indicate VEH (n = 8 DMBA, n = 8 VEH), E 2 (n = 8 DMBA, n = 7 VEH), raloxifene (n = 10 DMBA, n = 7 VEH), and E 2 + raloxifene (n = 10 DMBA, n = 7 VEH), respectively.
testing to mimic physiological rise in E 2 of young intact rats across the estrous cycle (Walf and Frye, 2009a, 2009b) . This dosing increased the incidence of tumors and the number of tumors formed (Walf and Frye, 2009a, 2009b) . More chronic dosing, such as 5 mg/kg of estradiol valerate daily for 6 months, had an opposite effect to reduce DMBA-induced tumor growth (Callejo et al., 2005) . In addition to different E 2 regimen, these studies Mean ( + SEM) duration spent immobile in the forced swim test of ovariectomized rats administered vehicle (VEH) or 7,12dimethylbenz(a)anthracene (DMBA), and VEH, E 2 and/or raloxifene. *Significant effect of E 2 and/or raloxifene versus VEH (P r 0.05). Simple regression analyses are included at the top of the figure. Open symbols indicate the VEH condition and closed symbols indicate the DMBA condition. Circles, squares, triangles, and diamonds indicate VEH (n = 8 DMBA, n = 8 VEH), E 2 (n = 8 DMBA, n = 7 VEH), raloxifene (n = 10 DMBA, n = 7 VEH), and E 2 + raloxifene (n = 10 DMBA, n = 7 VEH), respectively. differ in the strain of rats and DMBA dosing utilized, which may also account for some of the inconsistencies observed for modulation of tumor progression by E 2 .
Another question that needs to be addressed is the mechanism for these effects on peripheral tissues and behavior. For instance, studies to date suggest that these effects of E 2 on lordosis and affective behavior may partly be because of actions of E 2 through ERs, specifically at the ERa isoform in the hypothalamus and ERb in the hippocampus, respectively (Etgen, 1987; Ogawa et al., 1998; Walf and Frye, 2007b, 2008; Mazzucco et al., 2008; Walf, 2010) . The influence of other ER-rich brain targets for these effects on anxiety and depression behavior, such as the amygdala, raphe nucleus, and frontal cortex, are also of interest (Krezel et al., 2001; Hughes et al., 2008; Donner and Handa, 2009) . In this study, the mechanisms for observed behavioral and peripheral effects of E 2 and raloxifene were not elucidated, but recent evidence suggest that the effects of E 2 or SERMs in the brain and periphery may act at ERb and ERa, respectively, for their trophic actions (Jensen et al., 2010; Walf, 2010) .
Ongoing studies in our laboratory are focused on elucidating whether actions at these ER forms, and the downstream pathways that they activate, may be related to the discernible effects of E 2 and SERMs for brain function and proliferation in peripheral tissues.
The present results support the few studies to date that have investigated the functional effects of raloxifene on central nervous system processes. Similar to studies in women (Strickler et al., 2000; Jarkova et al., 2002) , raloxifene reduced anxiety-like behavior in the elevated plus maze in a manner congruous to E 2 ; however, there was no effect of this dosing of raloxifene for depression-like behavior in this study, using the one-trial forced swimming test. Twelve days of daily treatment with raloxifene (1 mg/kg), to Sprague-Dawely rats that were ovariectomized for 21 days before treatment was initiated, showed anti-depressant-like effects in the 2-day version of the forced swim test (Karahancer et al., 2008) . As described as follows, other studies have shown that raloxifene has modest, or no, effects, compared with E 2 (Berendsen et al., 2001; Pinilla et al., 2002; Gibbs et al., 2004; Karahancer et al., 2008) . Despite evidence for anti-depressant-like effects of raloxifene in the aforementioned study, there were no effects of this dosing of raloxifene for Morris water maze learning (Karahancer et al., 2008) . In a delayed matching to sample task, E 2 , but not raloxifene, improved performance with chronic dosing (Gibbs et al., 2004) . In another study, unlike E 2 , raloxifene did not reduce tail temperature in an ovariectomy-induced 'hot flash' rat model (Berendsen et al., 2001) . Similar to effects on lordosis in this study using once weekly, low dosing of raloxifene, no effects of low dosing of subchronic (3 days) raloxifene on lordosis behavior of adult ovariectomized rats were observed (Pinilla et al., 2002) . Some of these differences in the patterns of effects may be because of the dosing utilized. A low dosing of raloxifene was utilized in this study. At high dosages (over 1 mg/kg) raloxifene disrupted estrous cyclicity, and reduced fertility; these effects could be reversed with discontinuation of treatment (Hoyt et al., 1998) . As such, a lower dosage of raloxifene was intentionally utilized so that physiologically-relevant effects and/or interactions with E 2 could be observed and parsed out. Furthermore, the present results in rats extend the previous studies on the effects of E 2 and raloxifene co-administration for affective behavior in mice to begin to address whether there may be some species-specificity. We investigated the effects of E 2 and raloxifene for affective behavior among aged (24-28 months old) congenic female mice administered vehicle, E 2 (B0.1 mg/kg), and/or raloxifene (3 mg/kg). Unlike the present results in young, ovariectomized rats, we found that co-administration of E 2 + raloxifene had greater efficacy than E 2 or raloxifene alone to decrease anxietylike and depression-like behavior of these aged mice across several affective tasks (Walf and Frye, 2006) . These data suggest that there may be species-specificity effects for the effects of E 2 and raloxifene co-administration that need to be investigated further. Together, these data suggest that E 2 can enhance lordosis, and have effects to reduce anxiety and depression behavior, of rats, irrespective of coadministration of raloxifene; yet, raloxifene has more robust anxiety-reducing effects than effects to alter sexual or depression behavior in ovariectomized rats at the dosing utilized.
The results of this study confirm and extend previous studies investigating the trophic actions of raloxifene in peripheral tissues. Unlike E 2 , and the typically-prescribed SERM, tamoxifen, raloxifene is well-known for not increasing uterine proliferation, and the pattern of effects that we found in the present study supports these previous findings (Stygar et al., 2003; Yamamoto et al., 2005) . A question for further consideration is the role of raloxifene for tumorigenesis in our model. As in the present results, other studies have shown that DMBA typically produces adenocarcinomas and hormone-dependent tumors (Russo et al., 1990; Russo, 1996, 1998; Cheung et al., 2003) . Also, E 2 in high dosages alone, or when administered to DMBA-exposed rats, can increase tumorigenesis of female rats (Leung et al., 2003; Walf and Frye, 2009a, 2009b) . Effects of E 2 , alone or with raloxifene, in the present study, were more robust than those of raloxifene alone to increase tumor number and weight. Similarly, raloxifene does not reduce tumor burden from DMBA-induction among Sencar mice (Wurz et al., 2005) . However, raloxifene (3 mg/kg daily) to ovariectomized rats reduced tumorigenesis, compared with that observed in intact Sprague-Dawley rats (a more tumor prone rat model than Long-Evans rats) at the study endpoint of 6 months in another study using DMBA-induction (Callejo et al., 2005) . In the present study, raloxifene was administered in more moderate dosing, which could account for why raloxifene did not block the effects of E 2 , and/or have its own effects, on tumorigenesis. Also, synergistic effects of E 2 and raloxifene were not found. It may be of some use for future studies to examine dose-response of raloxifene for these effects; however, raloxifene alone altered open arm time in the plus maze, which suggests that the dosing utilized had some efficacy. Together, these data show that E 2 , but not raloxifene, can have clear trophic effects in uterine tissues and carcinogen-induced tumors.
Conclusion
This study is novel because an animal model was utilized to investigate the behavioral responses as well as peri pheral trophic effects of E 2 and raloxifene, which is a typical menopause hormone therapy for osteoporosis prevention. This study has clinical relevance as important health concerns for many postmenopausal women are breast cancer and osteoporosis with fractures, which increases morbidity and mortality substantially. Despite efficacy in treating osteoporosis, menopausal hormone therapy use is not advisable for many women who may be at increased risk for breast cancer as these therapies can further increase this risk. There is some recent evidence that raloxifene may even reduce primary breast cancer incidence in some high-risk women, but these results are not unequivocal to date (Thomsen and Kolesar, 2008; Nelson et al., 2009) . Some of the effects of raloxifene for tumors in reproductive tissues, bone density, and cholesterol levels may become refractory once treatment has ended, but long-term effects on central nervous system processes are not known. This study shows that the magnitude of the effects of raloxifene in an animal model may differ for central nervous system function and in peripheral tissues. The present results partially supported the a priori hypothesis that there would be discernible effects of E 2 and raloxifene, administered alone or when co-administered, for beneficial behavioral effects (anxiety, depression, sexual responding) versus trophic effects in peripheral, ER-rich tissues. The prediction that E 2 would have clear behavioral effects and trophic actions in peripheral tissues, and raloxifene would have a greater effect on behavioral effects than on growth in the periphery, was supported by these results.
These results also show that this dosing of raloxifene did not alter the effects of E 2 to increase tumor, pituitary, or uterine weight, but had an apparent, non-statistically significant effect to reduce the efficacy of E 2 for decreasing anxiety-like and depression-like behavior. Further investigation of the mechanisms, and functional trophic effects in the brain and periphery, of E 2 -mimetic therapies, such as raloxifene, is necessary.
